dr_yakupergun· @dr_yakupergun · X·· 4 days agoScore60
Body
In another meta-analysis of ours, to be presented at #ESMO26 , we evaluated whether adding carboplatin to taxane plus dual HER2 blockade improves pCR rates in neoadjuvant HER2+ breast cancer. Across 8 studies involving 2,529 patients, carboplatin did not significantly improve pCR rates (62.2% vs 61.7%), including across the evaluated clinical subgroups.
Heat 36 · 28 likes · 0 replies · 8 reposts
Conference abstracts
NCT05113251NCT05113251matched by - **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerRead the abstract →Source: dr_yakupergun · x.com